AQR Capital Management
ENTA icon

AQR Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

AQR Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.96M Buy
313,157
+78,322
+33% +$1.05M ﹤0.01% 1902
2025
Q4 		$3.7M Buy
234,835
+7,990
+4% +$101K ﹤0.01% 1759
2025
Q3 		$2.72M Sell
226,845
-169,265
-43% -$1.35M ﹤0.01% 1794
2025
Q2 		$2.99M Buy
396,110
+39,001
+11% +$235K ﹤0.01% 1555
2025
Q1 		$1.97M Buy
357,109
+311,010
+675% +$1.92M ﹤0.01% 1619
2024
Q4 		$265K Buy
46,099
+8,240
+22% +$79K ﹤0.01% 2556
2024
Q3 		$392K Sell
37,859
-22,146
-37% -$290K ﹤0.01% 2275
2024
Q2 		$778K Sell
60,005
-49,701
-45% -$671K ﹤0.01% 1868
2024
Q1 		$1.92M Sell
109,706
-93,558
-46% -$1.24M ﹤0.01% 1434
2023
Q4 		$1.91M Buy
203,264
+65,488
+48% +$610K ﹤0.01% 1368
2023
Q3 		$1.54M Buy
137,776
+118,320
+608% +$1.91M ﹤0.01% 1436
2023
Q2 		$416K Buy
19,456
+9,490
+95% +$280K ﹤0.01% 1838
2023
Q1 		$403K Sell
9,966
-7,261
-42% -$347K ﹤0.01% 1843
2022
Q4 		$801K Buy
17,227
+7,508
+77% +$342K ﹤0.01% 1629
2022
Q3 		$504K Buy
9,719
+2,229
+30% +$130K ﹤0.01% 1778
2022
Q2 		$354K Sell
7,490
-503
-6% -$27.3K ﹤0.01% 1802
2022
Q1 		$569K Sell
7,993
-6,120
-43% -$398K ﹤0.01% 1771
2021
Q4 		$1.05M Buy
14,113
+7,554
+115% +$593K ﹤0.01% 1534
2021
Q3 		$373K Sell
6,559
-1,407
-18% -$69.6K ﹤0.01% 1967
2021
Q2 		$351K Sell
7,966
-208
-3% -$10.2K ﹤0.01% 2004
2021
Q1 		$403K Sell
8,174
-27,623
-77% -$1.38M ﹤0.01% 1915
2020
Q4 		$1.51M Sell
35,797
-8,400
-19% -$370K ﹤0.01% 1306
2020
Q3 		$2.02M Sell
44,197
-18,029
-29% -$874K ﹤0.01% 1105
2020
Q2 		$3.12M Sell
62,226
-15,729
-20% -$814K 0.01% 962
2020
Q1 		$4.01M Sell
77,955
-37,276
-32% -$1.99M 0.01% 851
2019
Q4 		$7.12M Sell
115,231
-22,604
-16% -$1.4M 0.01% 860
2019
Q3 		$8.28M Buy
137,835
+13,732
+11% +$1.02M 0.01% 811
2019
Q2 		$10.5M Sell
124,103
-18,461
-13% -$1.66M 0.01% 760
2019
Q1 		$13.6M Sell
142,564
-45,235
-24% -$4.06M 0.01% 694
2018
Q4 		$13.3M Buy
187,799
+58,463
+45% +$4.48M 0.02% 650
2018
Q3 		$11.1M Buy
129,336
+8,936
+7% +$895K 0.01% 753
2018
Q2 		$14M Sell
120,400
-13,009
-10% -$1.3M 0.01% 679
2018
Q1 		$10.8M Sell
133,409
-21,773
-14% -$1.68M 0.01% 753
2017
Q4 		$9.11M Sell
155,182
-2,811
-2% -$141K 0.01% 818
2017
Q3 		$7.39M Buy
157,993
+20,270
+15% +$815K 0.01% 888
2017
Q2 		$4.96M Buy
137,723
+13,669
+11% +$437K 0.01% 1026
2017
Q1 		$3.82M Buy
124,054
+10,260
+9% +$320K 0.01% 1127
2016
Q4 		$3.81M Buy
113,794
+9,977
+10% +$286K 0.01% 1145
2016
Q3 		$2.76M Buy
103,817
+57,559
+124% +$1.34M ﹤0.01% 1261
2016
Q2 		$1.02M Buy
46,258
+2,822
+6% +$73.9K ﹤0.01% 1612
2016
Q1 		$1.28M Sell
43,436
-7,567
-15% -$211K ﹤0.01% 1478
2015
Q4 		$1.68M Sell
51,003
-3,471
-6% -$113K ﹤0.01% 1321
2015
Q3 		$1.97M Buy
54,474
+5,226
+11% +$224K ﹤0.01% 1135
2015
Q2 		$2.22M Buy
49,248
+7,786
+19% +$303K ﹤0.01% 1142
2015
Q1 		$1.27M Sell
41,462
-17,518
-30% -$682K ﹤0.01% 1314
2014
Q4 		$3M Sell
58,980
-220
-0.4% -$9.85K 0.01% 1106
2014
Q3 		$2.34M Buy
59,200
+38,300
+183% +$1.53M 0.01% 1184
2014
Q2 		$900K Buy
+20,900
New +$797K ﹤0.01% 1700

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AQR Capital Management's ENTA Position: Q1 2026 in Review

AQR Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 33% in Q1 2026, buying an estimated $1.05M and bringing the position to 313,157 shares worth $3.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1902.

AQR Capital Management first reported a position in ENTA in Q2 2014 and has held it in 48 quarters since. The position peaked at $14M in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • AQR Capital Management held 313,157 shares of Enanta Pharmaceuticals worth $3.96M as of Q1 2026.
  • AQR Capital Management bought 78,322 Enanta Pharmaceuticals shares in Q1 2026, an estimated $1.05M.
  • Enanta Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1902 holding.
  • AQR Capital Management first reported a position in Enanta Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
  • AQR Capital Management's Enanta Pharmaceuticals position peaked at $14M in Q2 2018.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.